Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Bengaluru company, global initiative to take new compound against superbugs to patients

13 June 2024

Times India Logo

 

11 June 2024 

BENGALURU: The Global Antibiotic Research & Development Partnership (GARDP) and Bengaluru-based Bugworks Research Inc are collaborating to co-develop a promising new antibiotic compound — “BWC0977” — with broad-spectrum antibiotic activity against multidrug-resistant bacteria that cause life-threatening infections. As per the agreement, GARDP will provide up to $20 million to Bugworks in technical and financial support for the pharmaceutical and clinical co-development of BWC0977.